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Objective: Peripheral treatment with the cholinergic agonist pilocarpine increases salivary
gland blood flow and induces intense salivation that is reduced by the central injection of
moxonidine (a2-adrenoceptors/imidazoline agonist). In the present study, we investigated
the effects of the intracerebroventricular (i.c.v.) injection of pilocarpine alone or combined
with moxonidine also injected i.c.v. On submandibular/sublingual gland (SSG) vascular
resistance. In addition, the effects of these treatments on arterial pressure, heart rate and on
mesenteric and hindlimb vascular resistance were also tested.
Design: Male Holtzman rats with stainless steel cannula implanted into lateral ventricle and
anaesthetized with urethane + a-chloralose were used.
Results: Pilocarpine (500 nmol/1 ml) injected i.c.v. Reduced SSG vascular resistance and
increased arterial pressure, heart rate and mesenteric vascular resistance. Contrary to
pilocarpine alone, the combination of moxonidine (20 nmol/1 ml) and pilocarpine injected
i.c.v. Increased SSG vascular resistance, an effect abolished by the pre-treatment with the
a2-adrenoceptor antagonist yohimbine (320 nmol/2 ml). The increase in arterial pressure,
heart rate and mesenteric resistance was not modified by the combination of moxonidine
and pilocarpine i.c.v.
Conclusion: These results suggest that the activation of central a2-adrenoceptors may
oppose to the effects of central cholinergic receptor activation in the SSG vascular resis-
tance.
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Open access under the Elsevier OA license. 1. Introduction
Pilocarpine is a muscarinic cholinergic agonist used to reduce
dryness of the oral mucosa in patients affected by salivary
gland diseases.1,2 It is well accepted that pilocarpine stimu-
lates salivary secretion by acting on cholinergic receptors in
the salivary gland.1,2 This idea is supported by the sialogogue
effect of pilocarpine in isolated salivary glands.3* Corresponding author at: Department of Physiology and Biophysics,
Lineu Prestes, 1524, 05508-000, Sa˜o Paulo, Brazil. Tel.: +55 11 3091 776
E-mail address: tmoreira@icb.usp.br (T.S. Moreira).
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Open access under the Elsevier OA license. However, recent evidence suggests that peripheral admin-
istered pilocarpine can also activate muscarinic receptors in
the brain to stimulate salivation.4,5,6 The suggestion that
pilocarpine may act centrally to stimulate salivary secretion is
also reinforced by studies that have shown that salivation
induced by pilocarpine injected peripherally is reduced by
focal lesions in the forebrain.7–9 Pilocarpine injected periph-
erally also induces submandibular/sublingual gland (SSG)
vasodilation,10 an effect due to the direct action of pilocarpine Institute of Biomedical Science, University of Sa˜o Paulo, Av. Prof
4; fax: +55 11 3091 7285.
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central mechanisms.6
Moxonidine (a2-adrenoceptor/imidazoline receptor ago-
nist) is an anti-hypertensive drug that acts centrally to reduce
sympathetic nerve discharge.11–14 Moxonidine injected i.c.v.
reduces peripheral pilocarpine-induced salivation and vaso-
dilation in the SSG.4,10,15 The reduction of pilocarpine-induced
salivation produced by moxonidine injected i.c.v depends on
the activation of central a2-adrenoceptors,
4,15 however, the
receptor subtypes involved in the moxonidine inhibition of
pilocarpine-induced SSG vasodilation have not been charac-
terized.
Therefore, in the present study we investigated the effects
of i.c.v. injection of pilocarpine alone or combined with i.c.v.
moxonidine on SSG, mesenteric and hindlimb blood flow and
vascular resistance, mean arterial pressure (MAP) and heart
rate (HR). Additionally, we also investigated the effects of
yohimbine (a2-adrenoceptor antagonist) injected i.c.v. com-
bined with moxonidine and pilocarpine i.c.v. on MAP, HR and




Male Holtzman rats weighing 300–350 g were used. The
animals were housed individually in stainless steel cages in
a room with controlled temperature (23  2 8C) and humidity
(55  10%). Lights were on from 7:00 am to 7:00 pm. Guabi rat
chow (Paulı´nia, SP, Brazil) and tap water were available
ad libitum. The experimental protocols were approved by the
Animal Experimentation Ethics Committee of the Federal
University of Sa˜o Paulo.
2.2. Brain surgery
Rats were anaesthetized with intraperitoneal (i.p.) injection of
ketamine (80 mg/kg of body wt) combined with xylazine (7 mg/
kg of body wt) and placed in a stereotaxic frame (model 900,
David Kopf Instruments). The skull was levelled between
bregma and lambda. A stainless steel cannula
(10 mm  0.6 mm o.d.) was implanted into the lateral cerebral
ventricle (LV) using the following stereotaxic coordinates:
0.3 mm caudal to bregma, 1.5 mm lateral to midline and
3.6 mm below the dura mater. The cannula was fixed to the
cranium with dental acrylic resin and jeweller screws. Rats
received a prophylactic dose of penicillin (30,000 IU) given
intramuscularly and a subcutaneous injection of the analgesic
Ketoflex (ketoprofen 1%, 0.03 ml/rat) post-surgically. After the
surgery, the rats were maintained in individual box with
free access of tap water and food pellets for at least 7 days
before the tests.
2.3. Drugs
Moxonidine hydrochloride (20 nmol/1 ml), a gift from Solvay
Pharma (Germany), pilocarpine hydrochloride (500 nmol/
1 ml) and yohimbine hydrochloride (320 nmol/2 ml) fromSigma Chemical Co., USA were injected i.c.v. A mix of
propylene glycol/water 2:1 was used as vehicle for yohimbine
and moxonidine because these drugs at the doses used are
not soluble in saline. Pilocarpine was dissolved in isotonic
saline.
The dose of pilocarpine used in the present study was
based on a previous study employing pilocarpine i.c.v. to
induce salivation in rats.7 The doses of yohimbine and
moxonidine were based on previous studies that have shown
the effects of different doses of yohimbine and moxonidine on
pilocarpine-induced salivation, water and sodium intake and
cardiovascular responses.4,16,17
2.4. Cerebral injections
Injections into the LV were made using 10 ml Hamilton
syringes connected by polyethylene tubing (PE-10) to injec-
tion cannulas 2 mm longer than the guide cannulas
implanted into the brain. The volume injected into the LV
was 1 or 2 ml.
2.5. Arterial pressure and heart rate recordings
On the day of the experiment rats were anaesthetized with
urethane (1.2 g/kg of body weight i.v.) and a-chloralose
(60 mg/kg of body weight i.v.) (after the induction with 1%
halothane in 100% O2). A femoral artery catheter (PE-10
connected to PE-50) was implanted for the record of pulsatile
arterial pressure, mean arterial pressure (MAP) and heart rate
(HR). A femoral vein catheter was implanted for administra-
tion of anaesthetic. To record pulsatile arterial pressure, MAP
and HR, the arterial catheter was connected to a Statham
Gould (P23 Db) pressure transducer coupled to a pre-amplifier
(model ETH-200 Bridge Bio Amplifier, CB Sciences) and to a
Powerlab computer recording system (model Powerlab 16SP,
ADInstruments). Recordings began 10 min after the connec-
tion of the arterial line to the pressure transducer. MAP and
HR were continuously recorded during 1 h and were analysed
at every 5 min. Baseline values were recorded for 10 min and
were analysed immediately before yohimbine or vehicle
injection (first treatment). These values were used as
reference to calculate the changes produced by the treat-
ments.
2.6. Submandibular/sublingual gland, superior
mesenteric and low abdominal aorta artery blood flow
recordings
Immediately after vein and artery catheterization, an incision
was made in ventral midline of the neck to localize the right
submandibular/sublingual gland (SSG) complex and the artery
that irrigates the SSG complex. The SSG artery, a cervical
branch of external maxillary artery is usually larger just above
the anterior margin of posterior belly of digastricus.6,10 The
artery that irrigates the SSG complex was isolated and a
miniature pulsed Doppler flow probe (Iowa Doppler Products;
Iowa City, IA) was perfectly adjusted around the artery to
record blood flow.
A midline laparotomy was also performed and miniature
pulsed Doppler flow probes were placed around the superior
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measurement of mesenteric and hindlimb blood flow,
respectively. The probes were fixed to the surrounding tissues
with suture thread. Data from animals in which the probes
moved during the experiment were not considered for
analysis.
The flow probes were connected to a Doppler flowmeter
(Dept of Bioengineering, University of Iowa, Iowa City, IA)
coupled to a Powerlab computer record system (model
Powerlab 16SP, ADInstruments) for blood flow recording.
Details of the Doppler flow recording technique, including the
reliability of the method for estimation of flow velocity, have
been described previously.18 Relative SSG, mesenteric and
hindlimb vascular resistance changes were calculated as the
ratio of MAP and Doppler shift.
Blood flow was continuously recorded for 1 h. Blood flow
and vascular resistance were analysed for every 5 min.
Baseline values were recorded for 10 min and were analysed
immediately before yohimbine or vehicle injection (first
injection). The values were used as reference to calculate
the changes produced by the treatments.
2.7. Histology
After the experiments, Evans blue (100 nl of a 2% solution) was
microinjected into the LV for histological analysis. The animals
were deeply anaesthetized with urethane (1.2 g/kg of body
weight i.v.) and a-chloralose (60 mg/kg of body weight i.v.).
Saline followed by 10% buffered formalin was perfused through
the heart. The brains were frozen, cut coronally into 50 mm
sections and stained with Giemsa stain. Only animals with
injections into the LV were considered for statistical analysis.Fig. 1 – Changes in (A) blood flow and (B) vascular resistance in
pilocarpine (500 nmol/1 ml) injected i.c.v. in rats pre-treated wit
moxonidine (20 nmol/1 ml) or vehicle injected i.c.v. The results 
*Different from vehicle + vehicle + saline (Student–Newman–Keu2.8. Statistical analysis
All values were expressed as means  SEM. Statistical
analysis was performed using two-way analysis of variance
(ANOVA) with repeated measures followed by Student–
Newman–Keuls post hoc tests to determine significant
differences between groups. Significance level was set at
p < 0.05.
2.9. Experimental protocols
All studies were performed in rats anaesthetized with
urethane (1.2 g/kg of body weight i.v.) and a-chloralose
(60 mg/kg of body weight i.v.). After 10 min of control
(baseline) recording of MAP, HR and blood flow velocity in
SSG, SM and abdominal aorta arteries, yohimbine (320 nmol/
2 ml) or vehicle was injected i.c.v. Moxonidine (20 nmol/1 ml)
or vehicle was injected i.c.v. 15 min after central injection of
yohimbine or vehicle. Pilocarpine (500 nmol/1 ml) or saline
was injected i.c.v. 15 min after the i.c.v. injection of
moxonidine or vehicle. The recordings stopped 30 min after
the last injection.
To study the involvement of central a2-adrenoceptor
on the association of cardiovascular effects of central
moxonidine and pilocarpine, 4 groups of rats were used:
(1) a control group that received vehicle i.c.v. followed by
vehicle and saline i.c.v.; (2) a group injected with
yohimbine i.c.v. followed by moxonidine and pilocarpine
i.c.v.; (3) a group treated with vehicle i.c.v. Followed by
moxonidine and pilocarpine i.c.v.; (4) a group that
received vehicle i.c.v. Followed by vehicle and pilocarpine
i.c.v. the submandibular/sublingual gland (SSG) produced by
h yohimbine (320 nmol/2 ml) or vehicle combined with
are represented as means W SEM. n = number of rats.
ls test, p < 0.05).
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3.1. Changes in the SSG vascular resistance and blood
flow produced by pilocarpine i.c.v. in rats pre-treated with
moxonidine i.c.v. alone or combined with yohimbine i.c.v.
Pilocarpine (500 nmol/1 ml) injected i.c.v. reduced SSG vascular
resistance (34  11%, vs. saline: 5  5%) [F (3, 17) = 118,13;
p < 0.01] and increased SSG blood flow (43  18%, vs. saline:
6  3%) [F (3, 17) = 105,66; p < 0.01] (Fig. 1).
Contrary to the effects of pilocarpine injected i.c.v. alone,
the SSG vascular resistance increased (80  36%) and the SSG
blood flow was reduced (45  15%) by the treatment with
pilocarpine i.c.v. combined with moxonidine (20 nmol/1 ml)
i.c.v. (Fig. 1).
The pre-treatment with yohimbine (320 nmol/2 ml) injected
i.c.v. abolished the increase in SSG vascular resistance (3  6%,
vs: moxo + pilo: 80  36%) and the vasodilatation (7  13%, vs:
moxo + pilo: 45  15%) produced by combining moxonidine
and pilocarpine i.c.v. (Fig. 1).
3.2. Changes in MAP and HR and in the vascular
resistance and blood flow in the SM artery and hindlimb
produced by pilocarpine injected i.c.v. in rats pre-treated with
moxonidine i.c.v. alone combined with yohimbine i.c.v.
Pilocarpine (500 nmol/1 ml) injected i.c.v. induced pressor
responses (21  4 mmHg, vs. saline: 2  2 mmHg) [F (3,
17) = 63,47; p < 0.05] and tachycardia (15  4 bpm, vs. vehicle
3  4 bpm) [F (3, 17) = 44,12; p < 0.05] and increased vascular
resistance (28  4% vs. saline: 6  3%) [F (3, 17) = 46,19;Fig. 2 – Changes in (A) mean arterial pressure (MAP) and (B) hea
1 ml) injected i.c.v. in rats pre-treated with yohimbine (320 nmo
or vehicle injected i.c.v. The results are represented as means W
vehicle + vehicle + saline (Student–Newman–Keuls test, p < 0.05p < 0.05] and reduced blood flow in the SM artery
(13  6% vs. saline: 2  1%) [F (3, 17) = 53,07; p < 0.05],
without changing hindlimb vascular resistance or blood
flow (Figs. 2–4).
Prior injection of moxonidine (20 nmol/1 ml) i.c.v. alone or
combined with yohimbine (320 nmol/2 ml) did not modify
the pressor response (18  4 and 16  3 mmHg, respectively),
thetachycardia (12  4and13  3 bpm,respectively), theincrease
in SM vascular resistance (20  4% and 19  4%, respectively) and
the reduction of blood flow (10  4% and 12  3%, respectively)
produced by i.c.v. pilocarpine (Figs. 2 and 3).
The baseline MAP and HR immediately before yohimbine or
vehicle injections in each group of rats are presented in
Table 1.
4. Discussion
The present results show that central injections of pilocar-
pine reduce SSG vascular resistance and the increase MAP,
HR and mesenteric vascular resistance. Contrary to the
reduction in the salivary gland vascular resistance, the
combination of moxonidine and pilocarpine injected i.c.v.
increased SSG vascular resistance, an effect abolished by the
previous injection of yohimbine i.c.v. The changes in
mesenteric vascular resistance, MAP and HR produced by
pilocarpine i.c.v. were not altered by the central injection of
moxonidine. Hindlimb vascular resistance was not affected
by either treatment. These results suggest that the activation
of central a2-adrenoceptors may oppose to the effects of
central cholinergic receptor activation in the SSG vascular
resistance.rt rate (HR) produced by produced by pilocarpine (500 nmol/
l/2 ml) or vehicle combined with moxonidine (20 nmol/1 ml)
 SEM. n = number of rats. *Different from
).
Fig. 3 – Changes in (A) blood flow and (B) vascular resistance in superior mesenteric (SM) artery produced by pilocarpine
(500 nmol/1 ml) injected i.c.v. in rats pre-treated with yohimbine (320 nmol/2 ml) or vehicle combined with moxonidine
(20 nmol/1 ml) or vehicle injected i.c.v. The results are represented as means W SEM. n = number of rats. *Different from
vehicle + saline (Student–Newman–Keuls test, p < 0.05).
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MAP, HR and on SSG and mesenteric resistances were
similar to those produced by peripheral injections of
pilocarpine, which reinforces the suggestion that pilocar-
pine injected peripherally may act centrally to reduce SSGFig. 4 – Changes in (A) blood flow and (B) vascular resistance in
i.c.v. in rats pre-treated with yohimbine (320 nmol/2 ml) or vehi
injected i.c.v. The results are represented as means W SEM. n = 
Newman–Keuls test, p < 0.05).vascular resistance and to increase MAP, HR and mesen-
teric vascular resistance.6,10 In addition to the central
effects, pilocarpine injected peripherally may also produce
SSG vasodilation by acting directly in the salivary glands.
In spite of this direct effect on salivary glands, moxonidine hindlimb produced by pilocarpine (500 nmol/1 ml) injected
cle combined with moxonidine (20 nmol/1 ml) or vehicle
number of rats. *Different from vehicle + saline (Student–
Table 1 – Baseline MAP and HR in the groups of rats that received pilocarpine or saline injected i.c.v. after the pre-
treatment with yohimbine or vehicle combined with moxonidine or vehicle injected i.c.v.
Treatments Baseline MAP (mmHg) Baseline HR (bpm)
Vehicle + vehicle + saline (i.c.v.) (n = 6) 102  4 382  9
Vehicle + vehicle + pilocarpine (i.c.v.) (n = 7) 100  3 373  10
Vehicle + moxonidine + pilocarpine (i.c.v.) (n = 7) 101  4 388  12
Yohimbine + moxonidine + pilocarpine (i.c.v.) (n = 8) 103  4 380  11
The results are represented as means  SEM. n = number of rats. Pilocarpine (500 nmol/1 ml); moxonidine (20 nmol/1 ml); yohimbine (320 nmol/
2 ml).
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nously also increased SSG vascular resistance,10 similar to
the effects of moxonidine combined with pilocarpine i.c.v.
(present results). Moxonidine injected i.c.v. alone also
increases SSG vascular resistance,10 which suggests that
the activation of central a2-adrenoceptors overcomes the
effects central cholinergic activation resulting in increased
SSG vascular resistance when pilocarpine is combined with
moxonidine both injected i.c.v.
The importance and the involvement of the central a2-
adrenoceptors in the inhibition of salivation were shown
previously by injecting clonidine intracisternally in cats that
received electrical stimulation of brainstem parasympathetic
nuclei.19 The effect of clonidine was inhibited by prior
intracisternal injection of yohimbine. Previous studies also
showed that the activation of central a2-adrenoceptors with
moxonidine reduces salivation and abolishes the increase in
the SSG blood flow produced by peripheral injection of
pilocarpine.4,10 The present results extend the conclusion of
the previous studies showing that: (1) central injection of
pilocarpine reduces SSG vascular resistance, similarly to the
activation of the parasympathetic output or to peripheral
injection of pilocarpine; (2) the increase in the SSG vascular
resistance after combining central injection of pilocarpine and
moxonidine results from the activation of central a2-adreno-
ceptor by moxonidine.
Pilocarpine at the dose used in the present study reduces
salivary gland vascular resistance and increases mesenteric
vascular resistance without changing hindlimb vascular
resistance. The opposite effects on vascular resistance suggest
that pilocarpine activates different mechanisms producing
specific adjustments in vascular resistance and blood flow in
different regions of the body. Pilocarpine injected centrally
produces:(1) decrease in the SSG vascular resistance and no
change in the hindlimb; (2) increase in MAP that seems to be
dependent on the increase in mesenteric vascular resistance;
(3) increase in HR that may be involved in pressor pathway. It
is well known that the central activation of cholinergic
receptors stimulates sympathetic activity and vasopressin
release, causing an increase in MAP.20,21 Combining the
increase in MAP and the reduced salivary gland vascular
resistance, central injection of pilocarpine produces a strong
increase in blood flow to the salivary glands and these effects
may explain why pilocarpine is so effective at inducing
salivary secretion.
Despite of the anti-hypertensive properties of moxonidine
(a2-adrenoceptor and imidazoline agonist
12–14,24), no change in
pilocarpine-induced vasoconstriction and pressor responses
was observed following the treatment with moxonidine intothe lateral cerebral ventricle as previously demonstrated for
pilocarpine injected peripherally.10 Studies have demonstrat-
ed that moxonidine acts in the brainstem, particularly in
rostral ventrolateral medulla (RVLM), to reduce sympathetic
outflow and blood pressure.11–14 In the present study,
moxonidine was injected into the lateral cerebral ventricle
and in this case the main areas reached by moxonidine were
forebrain areas. The results suggest that the activity of the
cholinergic pressor mechanisms in the forebrain is not
modified by the activation of a2-adrenoceptors or imidazoline
receptors with i.c.v. injection of moxonidine.
The vasoconstriction in the salivary gland induced by
moxonidine may be the result of the activation of a
vasoconstrictor or removal of the vasodilator mechanism to
the salivary gland. The latter seems less likely because
vasodilator tone to the salivary glands is rather small.22
Whatever the mechanism activated by central moxonidine,
the increase in salivary gland vascular resistance produced by
i.c.v. moxonidine was not modified by peripheral10 and central
injection (present data) of pilocarpine.
It seems that pilocarpine acting centrally activates both
salivary gland secretion and vasodilation.7,8,10 Because saliva-
tion depends on secretory mechanisms and on the increase in
blood flow to the glands,23 reduction in salivation may occur if
one or both mechanisms are affected. The activation of a2-
adrenoceptor with moxonidine reduces the salivary secretion
and the vasodilation induced by pilocarpine.15,10 Therefore, it
is possible that moxonidine inhibits pilocarpine-induced
salivation at least partially by reducing salivary gland blood
flow. Besides this, the vasoconstriction and the reduction of
the blood flow to the salivary glands produced by the
activation of the central a2-adrenoceptors is probably impor-
tant for the sensation of dryness in the mouth by patients
treated with moxonidine or the same type of drugs.
In summary, the present results suggest that central
cholinergic and a2-adrenergic mechanisms have opposite
roles in the control of the salivary gland vascular resistance
and blood flow. However, the increase in MAP, HR and
mesenteric vascular resistance produced by the cholinergic
activation in the forebrain is not affected by central a2-
adrenoceptor activation, suggesting that different central
mechanisms are activated by pilocarpine to produce the
changes in the vascular resistance in different vascular
beds.
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